Macrocure (MCUR) Tops Q1 EPS by 1c

Macrocure (NASDAQ: MCUR) reported Q1 EPS of ($0.38), $0.01 better than the analyst estimate of ($0.39).

Guidance

The Company reiterates that expected cash used for its ongoing operating activities in 2015 will be $21-$25 million, reflecting anticipated expenditures to complete its current Phase III clinical trials in process this year. As previously disclosed, that range excludes approximately $4 million in potential capital expenditures in 2015 primarily related to the Company's new U.S. manufacturing facility

For earnings history and earnings-related data on Macrocure (MCUR) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
• Azitra, Inc. (AZTR) Tops Q2 EPS by 54c